Axitinib as a third or further line of treatment in renal cancer: a single institution experience

BACKGROUND: Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsironis, G., Liontos, M., Kyriazoglou, A., Koutsoukos, K., Tsiara, A., Kaparelou, M., Zakopoulou, R., Cohen, A., Skafida, E., Fontara, S., Zagouri, F., Bamias, A., Dimopoulos, M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265645/
https://www.ncbi.nlm.nih.gov/pubmed/32487200
http://dx.doi.org/10.1186/s12894-020-00618-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265645/
https://www.ncbi.nlm.nih.gov/pubmed/32487200
http://dx.doi.org/10.1186/s12894-020-00618-1

Ejemplares similares